Cerebral palsy is the most common cause of severe physical disability in childhood. Spasticity is a common and disabling symptom for many patients with cerebral palsy. Therapy for spasticity is symptomatic with the aim of increasing functional capacity and relieving discomfort. Spasticity treatment by orally administered drugs and intramuscular chemodenervation agents has become more frequent. ...

BACKGROUND Pain management is a high priority for patients with rheumatoid arthritis (RA). Muscle relaxants include drugs that reduce muscle spasm (for example benzodiazepines such as diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan) and non-benzodiazepines such as metaxalone (Skelaxin) or a combination of paracetamol and orphenadrine (Muscol)) and drugs that prevent increased muscle to...

Chau, Connie, Hugues Barbeau, and Serge Rossignol. Effects review, see Rossignol 1996). For example, in in vitro neonaof intrathecal a1and a2-noradrenergic agonists and norepinephrine tal rat preparation, locomotor activity have been found to be on locomotion in chronic spinal cats. J. Neurophysiol. 79: 2941– released by EAA (Cazalets et al. 1990; Kudo and Yamada 2963, 1998. Noradrenergic drugs...

Background: The objective of this study was to investigate whether an anti-spasticity medication can facilitate the effects of robotic locomotor treadmill training (LTT) to improve gait function in people with incomplete spinal cord injury (SCI). Methods: Individuals with chronic incomplete SCI were recruited and carried out a 4 week intervention of either locomotor treadmill training (LTT) alo...